Thomas Richard Kassberg - Oct 23, 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
CBO & EVP
Signature
/s/ Karah Parschauer, attorney-in-fact
Stock symbol
RARE
Transactions as of
Oct 23, 2023
Transactions value $
-$1,033,638
Form type
4
Date filed
10/24/2023, 05:22 PM
Previous filing
Mar 3, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Options Exercise $274K +39.9K +16.15% $6.86* 287K Oct 23, 2023 Direct
transaction RARE Common Stock Sale -$1.31M -39.9K -13.91% $32.78 247K Oct 23, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RARE Stock Option (Right to Buy) Options Exercise $0 -39.9K -100% $0.00* 0 Oct 23, 2023 Common Stock 39.9K $6.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3 The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.